Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 6, 2008, Pages 691-697

  Yang, J ^a   Bogni, A ^a   Cheng, C ^a   Bleibel, W K ^b   Cai, X ^a   Fan, Y ^a   Yang, W ^a   Rocha, J C C ^a   Pei, D ^a   Liu, W ^a   Dolan, M E ^b   Pui, C H ^a,c,d   Relling, M V ^a,c,d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG CYTOTOXICITY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SECOND CANCER; THERAPY RELATED ACUTE MYELOID LEUKEMIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT;

EID: 56549130966     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.86     Document Type: Article

References (48)

1. Pui, C.H. & Relling, M.V. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br. J. Haematol. 109, 13-23 (2000).
2. Ratain, M.J. et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70, 1412-1417 (1987).
3. Armstrong, S.A., Golub, T.R. & Korsmeyer, S.J. MLL-rearranged leukemias: insights from gene expression profiling. Semin. Hematol. 40, 268-273 (2003).
4. Li, Z.Y., Liu, D.P. & Liang, C.C. New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia 19, 183-190 (2005).
5. Super, H.J. et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82, 3705-3711 (1993).
6. Pui, C.H. Epipodophyllotoxin-related acute myeloid leukaemia. Lancet 338, 1468 (1991).
7. Pui, C.H. et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 9, 1990-1996 (1995).
8. Pedersen-Bjergaard, J. & Philip, P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 78, 1147-1148 (1991).
9. Pedersen-Bjergaard, J., Andersen, M.K. & Johansson, B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J. Clin. Oncol. 16, 1897-1898 (1998).
10. Blanco, J.G., Edick, M.J. & Relling, M.V. Etoposide induces chimeric Mll gene fusions. FASEB J. 18, 173-175 (2004).
11. Mirault, M.E., Boucher, P. & Tremblay, A. Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot. Am. J. Hum. Genet. 79, 779-791 (2006).
12. Burden, D.A. & Osheroff, N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400, 139-154 (1998).
13. Berger, N.A., Chatterjee, S., Schmotzer, J.A. & Helms, S.R. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc. Natl. Acad. Sci. USA 33, 8740-8743 (1991).
14. Weinstock, D.M., Richardson, C.A., Elliott, B. & Jasin, M. Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair (Amst) 5, 1065-1074 (2006).
15. Sung, P.A., Libura, J. & Richardson, C. Etoposide and illegitimate DNA doublestrand break repair in the generation of MLL translocations: new insights and new questions. DNA Repair (Amst) 5, 1109-1118 (2006).
16. Hars, E.S., Lyu, Y.L., Lin, C.P. & Liu, L.F. Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. Cancer Res. 66, 8975-8979 (2006).
17. Sim, S.P. & Liu, L.F. Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis. J. Biol. Chem. 276, 31590-31595 (2001).
18. Le Deley, M.C. et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J. Clin. Oncol. 21, 1074-1081 (2003).
19. Schneider, D.T. et al. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J. Clin. Oncol. 17, 3226-3233 (1999).
20. Pui, C.H. et al. l-Asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9, 1680-1684 (1995).
21. Verdeguer, A. et al. Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide. Med. Pediatr. Oncol. 20, 48-52 (1992).
22. Sugita, K. et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am. J. Pediatr. Hematol. Oncol. 15, 99-104 (1993).
23. Kollmannsberger, C., Hartmann, J.T., Kanz, L. & Bokemeyer, C. Therapy-related malignancies following treatment of germ cell cancer. Int. J. Cancer 83, 860-863 (1999).
24. Kollmannsberger, C. et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J. Clin. Oncol. 16, 3386-3391 (1998).
25. Tebbi, C.K. et al. Dexrazoxane-associated risk for acute myeloid leukemia/ myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25, 493-500 (2007).
26. Shukla, S.J. & Dolan, M.E. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics 6, 303-310 (2005).
27. Meucci, M.A., Marsh, S., Watters, J.W. & McLeod, H.L. CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics 6, 59-63 (2005).
28. Watters, J.W., Kraja, A., Meucci, M.A., Province, M.A. & McLeod, H.L. Genomewide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. USA 101, 11809-11814 (2004).
29. Chen, C.L., Fuscoe, J.C., Liu, Q., Pui, C.H., Mahmoud, H.H. & Relling, M.V. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J. Natl. Cancer Inst. 88, 1840-1847 (1996).
30. Karp, J.E. & Smith, M.A. Modifying risks of secondary leukemias: is drug scheduling important? J. Natl. Cancer Inst. 88, 1787-1789 (1996).
31. Smith, M.A., McCaffrey, R.P. & Karp, J.E. The secondary leukemias: challenges and research directions. J. Natl. Cancer Inst. 88, 407-418 (1996).
32. Azarova, A.M. et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA 104, 11014-11019 (2007).
33. Relling, M.V. et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12, 346-352 (1998)
34. Pui, C.H. et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N. Engl. J. Med. 325, 1682-1687 (1991).
35. Chen, C.L., Fuscoe, J.C., Liu, Q. & Relling, M.V. Etoposide causes illegitimate V(D) J recombination in human lymphoid leukemic cells. Blood 88, 2210-2218 (1996).
36. Relling, M.V. et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101, 3862-3867 (2003).
37. Smith, R.E., Bryant, J., DeCillis, A. & Anderson, S.; National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J. Clin. Oncol. 21, 1195-1204 (2003).
38. Fisher, B. et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J. Clin. Oncol. 17, 3374-3388 (1999).
39. Germeshausen, M. et al. Granulocyte colony-stimulating factor receptor mutations in a patient with acute lymphoblastic leukemia secondary to severe congenital neutropenia. Blood 97, 829-830 (2001).
40. Barcellos-Hoff, M.H., Park, C. & Wright, E.G. Radiation and the microenvironment - tumorigenesis and therapy. Nat. Rev. Cancer 5, 867-875 (2005).
41. Seedhouse, C. & Russell, N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br. J. Haematol. 137, 513-529 (2007).
42. Hartford, C. et al. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia 21, 2128-2136 (2007).
43. Huang, R.S. et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl. Acad. Sci. USA 104, 9758-9763 (2007).
44. Huang, R.S., Kistner, E.O., Bleibel, W.K., Shukla, S.J. & Dolan, M.E. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol. Cancer Ther. 6, 31-36 (2007).
45. Zendegui, J.G., Vasquez, K.M., Tinsley, J.H., Kessler, D.J. & Hogan, M.E. In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res. 20, 307-314 (1992).
46. Rivera, G.K. et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 337, 61-66 (1991).
47. Evans, W.E., Relling, M.V., Rodman, J.H., Crom, W.R., Boyett, J.M. & Pui, C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338, 499-505 (1998).
48. Pui, C.H. et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92, 411-415 (1998).